


KRFK TFA

Cat. No.:	HY-P3970A
Molecular Formula:	C ₂₇ H ₄₇ N ₉ O ₅ ·xC ₂ HF ₃ O ₂
Sequence:	Lys-Arg-Phe-Lys
Sequence Shortening:	KRFK
Target:	TGF-β Receptor
Pathway:	TGF-beta/Smad
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 100 mg/mL * "≥" means soluble, but saturation unknown.
-----------------	--

BIOLOGICAL ACTIVITY

Description	KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders research ^[1] .
IC₅₀ & Target	TGF-β ^[1]
In Vitro	KRFK TFA (50 μM; 24 h) activates the secretion of TGF-β and reduces the expression of DC maturation markers in tsp-1 deficient bone marrow-derived dendritic cells (BMDCs) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	KRFK TFA (5 μg/5 μL/eyes; single dose) significantly prevents the development of chronic ocular surface inflammation in TSP-1 ^{-/-} mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Soriano-Romaní L, et al. Topical Application of TGF-β-Activating Peptide, KRFK, Prevents Inflammatory Manifestations in the TSP-1-Deficient Mouse Model of Chronic Ocular Inflammation. Int J Mol Sci. 2018 Dec 20;20(1):9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA